Different clinical characteristics and outcomes of hypertrophic cardiomyopathy with and without hypertension: seeking the truth

[1] [2] [3] Zhou B, Perel P, Mensah GA, et al. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol 2021; 18: 785−802. doi: 10.1038/s41569-021-00559-8 [4] Yildiz M, Oktay AA, Stewart MH, et al. Left ventricular hypertrophy and hypertension. Prog Cardiovasc Dis 2020; 63: 10−21. doi: 10.1016/j.pcad.2019.11.009 [5] Luo Q, Chen J, Zhang T, et al. Retrospective analysis of clinical phenotype and prognosis of hypertrophic cardiomyopathy complicated with hypertension. Sci Rep 2020; 10: 349. doi: 10.1038/s41598-019-57230-z [6] Karam R, Lever HM, Healy BP. Hypertensive hypertrophic cardiomyopathy or hypertrophic cardiomyopathy with hypertension? A study of 78 patients. J Am Coll Cardiol 1989; 13: 580−584. doi: 10.1016/0735-1097(89)90596-2 [7] Rastegar H, Boll G, Rowin EJ, et al. Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience. Ann Cardiothorac Surg 2017; 6: 353−363. doi: 10.21037/acs.2017.07.07 [8] Vanderlaan RD, Woo A, Ralph-Edwards A. Isolated septal myectomy for hypertrophic obstructive cardiomyopathy: an update on the Toronto General Hospital experience. Ann Cardiothorac Surg 2017; 6: 364−368. doi: 10.21037/acs.2017.05.12 [9] Kim LK, Swaminathan RV, Looser P, et al. Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US nationwide inpatient database, 2003–2011. JAMA Cardiol 2016; 1: 324−332. doi: 10.1001/jamacardio.2016.0252 [10] Wu G, Liu L, Zhou Z, et al. East Asian-specific common variant in TNNI3 predisposes to hypertrophic cardiomyopathy. Circulation 2020; 142: 2086−2089. doi: 10.1161/CIRCULATIONAHA.120.050384 [11] Wang J, Wang Y, Zou Y, et al. Malignant effects of multiple rare variants in sarcomere genes on the prognosis of patients with hypertrophic cardiomyopathy. Eur J Heart Fail 2014; 16: 950−957. doi: 10.1002/ejhf.144 [12] Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 2020; 142: e533−e557. doi: 10.1161/CIR.0000000000000938 [13] Wu X, Yuan X, Wang W, et al. Value of a machine learning approach for predicting clinical outcomes in young patients with hypertension. Hypertension 2020; 75: 1271−1278. doi: 10.1161/HYPERTENSIONAHA.119.13404 [14] Wu G, Liu J, Wang S, et al. N-terminal pro-brain natriuretic peptide and sudden cardiac death in hypertrophic cardiomyopathy. Heart 2021; 107: 1576−1583. doi: 10.1136/heartjnl-2020-317701 [15] Liu J, Zhao S, Yu S, et al. Patterns of replacement fibrosis in hypertrophic cardiomyopathy. Radiology 2022; 302: 298−306. doi: 10.1148/radiol.2021210914 [16] Schulz-Menger J, Bluemke DA, Bremerich J, et al. Standardized image interpretation and post-processing in cardiovascular magnetic resonance--2020 update: Society for Cardiovascular Magnetic Resonance (SCMR): board of trustees task force on standardized post-processing. J Cardiovasc Magn Reson 2020; 22: 19. doi: 10.1186/s12968-020-00610-6 [17] Shaw LJ, Berman DS, Picard MH, et al. Comparative definitions for moderate-severe ischemia in stress nuclear, echocardiography, and magnetic resonance imaging. JACC Cardiovasc Imaging 2014; 7: 593−604. doi: 10.1016/j.jcmg.2013.10.021 [18] Yang JY, Webster-Clark M, Lund JL, et al. Propensity score methods to control for confounding in observational cohort studies: a statistical primer and application to endoscopy research. Gastrointest Endosc 2019; 90: 360−369. doi: 10.1016/j.gie.2019.04.236 [19] Loncaric F, Nunno L, Mimbrero M, et al. Basal ventricular septal hypertrophy in systemic hypertension. Am J Cardiol 2020; 125: 1339−1346. doi: 10.1016/j.amjcard.2020.01.045 [20] Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35: 2733−2779. doi: 10.1093/eurheartj/ehu284 [21] Kato TS, Noda A, Izawa H, et al. Discrimination of nonobstructive hypertrophic cardiomyopathy from hypertensive left ventricular hypertrophy on the basis of strain rate imaging by tissue Doppler ultrasonography. Circulation 2004; 110: 3808−3814. doi: 10.1161/01.CIR.0000150334.69355.00 [22] Aronson SJ, Clark EH, Varugheese M, et al. Communicating new knowledge on previously reported genetic variants. Genet Med 2012; 14: 713−719. doi: 10.1038/gim.2012.19 [23] Walsh R, Thomson KL, Ware JS, et al. Reassessment of Mendelian gene pathogenicity using 7855 cardiomyopathy cases and 60,706 reference samples. Genet Med 2017; 19: 192−203. doi: 10.1038/gim.2016.90 [24] Ho CY, Day SM, Ashley EA, et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation 2018; 138: 1387−1398. doi: 10.1161/CIRCULATIONAHA.117.033200 [25] Harper AR, Goel A, Grace C, et al. Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity. Nat Genet 2021; 53: 135−142. doi: 10.1038/s41588-020-00764-0 [26] Weber MA. Coronary heart disease and hypertension. Am J Hypertens 1994; 7: 146S−153S. doi: 10.1093/ajh/7.10.146S [27] Kokubo Y, Matsumoto C. Hypertension is a risk factor for several types of heart disease: review of prospective studies. Adv Exp Med Biol 2017; 956: 419−426. doi: 10.1007/5584_2016_99 [28] Ammirati E, Contri R, Coppini R, et al. Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. Eur J Heart Fail 2016; 18: 1106−1118. doi: 10.1002/ejhf.541 [29] Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 2018; 39: 3021−3104. doi: 10.1093/eurheartj/ehy339 [30]

Herman LL, Padala SA, Ahmed I, et al. Angiotensin converting enzyme inhibitors (ACEI). In: StatPearls. Treasure Island (FL): StatPearls Publishing; August 5, 2022.

[31]

Hill RD, Vaidya PN. Angiotensin II receptor blockers (ARB). In: StatPearls. Treasure Island (FL): StatPearls Publishing; March 28, 2022.

[32] Weber KT, Brilla CG, Campbell SE, et al. Myocardial fibrosis: role of angiotensin II and aldosterone. Basic Res Cardiol 1993; 88: S107−S124. doi: 10.1007/978-3-642-72497-8_8 [33] Ho CY, Lakdawala NK, Cirino AL, et al. Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression. JACC Heart Fail 2015; 3: 180−188. doi: 10.1016/j.jchf.2014.08.003 [34] Mendes AS, Blascke de Mello MM, Parente JM, et al. Verapamil decreases calpain-1 and matrix metalloproteinase-2 activities and improves hypertension-induced hypertrophic cardiac remodeling in rats. Life Sci 2020; 244: 117153. doi: 10.1016/j.lfs.2019.117153

留言 (0)

沒有登入
gif